Please login to the form below

Not currently logged in
Email:
Password:

Piramal

This page shows the latest Piramal news and features for those working in and with pharma, biotech and healthcare.

India denies Vertex patent on cystic fibrosis drug Orkambi

India denies Vertex patent on cystic fibrosis drug Orkambi

The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.

Latest news

  • EMA unveils draft guidelines for Alzheimer’s disease research EMA unveils draft guidelines for Alzheimer’s disease research

    Although the last few years have seen a number of Alzeimer's diagnostics approved, among them GE Healthcare Vizamyl (flutemetamol) and Piramal's Neuraceq (florbetaben F18), research progress for a treatment

  • Piramal sells clinical research arm to Indoco Piramal sells clinical research arm to Indoco

    Dr Swati Piramal, vice chairman of Piramal Enterprises, told PMLiVE: “The clinical trial facility was for bioequivalence studies mainly for generics. ... Aditi Kare Panandikar, managing director of Indoco, commented: “We are extremely happy to have

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Lilly has LY2881835 in early clinical trials, while Piramal recently started trials of its P11187 candidate and Connexios Life Sciences has also brought CNX 011-67 into the clinic.

  • CHMP backs Piramal's Alzheimer's imaging agent CHMP backs Piramal's Alzheimer's imaging agent

    Neuraceq recommended for approval in Europe. Piramal is close to winning EU approval for its Alzheimer's disease (AD) diagnostic Neuraceq after a positive opinion from the EMA's Committee for ... Piramal acquired rights to Neuraceq from Bayer in 2012,

  • Abbott reports global sales of $9bn

    by strong performances in Russia, India and China and including contributions from the Solvay and Piramal acquisitions.

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    So when Janssen announced this month it had divested five injectable pain products to Piramal for $175m, it is assumed this was a consequence of low margins and manufacturing issues. ... 200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5

  • The pill branding The pill branding

    TV ads show desperate young women and crying girls. The slogan of the Indian manufacturer Piramal for the drug i-pill is: “Because prevention is better than abortion”.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics